GPCR Target: CHO-K1-Gαqi5 Gal1R
Authors: Paulo A. De Oliveira, Estefanía Moreno, Nil Casajuana-Martin, Verònica Casadó-Anguera, Ning-Sheng Cai, Gisela Andrea Camacho-Hernandez, Hu Zhu, Alessandro Bonifazi, Matthew D. Hall, David Weinshenker, Amy Hauck Newman, Diomedes E. Logothetis, Vicent Casadó, Leigh D. Plant, Leonardo Pardo, Sergi Ferré
Company: Integrative Neurobiology Section, USA; Medicinal Chemistry Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA; Laboratory of Molecular Neuropharmacology, Department of Biochemistry and Molecular Biomedicine, Faculty of Biology and Institute of Biomedicine, University of Barcelona, Barcelona, Spain; Laboratory of Computational Medicine, Biostatistics Unit, Faculty of Medicine, Autonomous University of Barcelona, Bellaterra, Spain; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA; Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA; Departments of Pharmaceutical Sciences, Chemistry and Chemical Biology and Center for Drug Discovery, School of Pharmacy at the Bouvé College of Health Sciences and College of Science, Northeastern University, Boston, MA, USA
Journal: Pharmacological Research, Volume 182, 2022, 106322,
